ESTRELLA IMMUNOPHARMA INC ESLA 深 滬
已收盤 09-05 16:00:00 美东时间
1.05
-0.030
-2.78%
華盛通- 最 高1.10
- 今 開1.10
- 成交量 2.30万股
- 最 低 1.04
- 昨 收 1.08
- 總市值 3797.39万
- 52周最高 1.78
- 市盈率 靜 --
- 換手率 0.06%
- 52周最低 0.63
- 委 比 -93.56%
- 總股本 3616.56万
- 歷史最高 33.00
- 量 比 0.40
- 振 幅 5.56%
- 歷史最低 0.00
- 每 手 1
- 風險率 0.15%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 潜在涨幅921.1%！Intensity Therapeutics获Brookline Capital升级至"买入"，目标价上调至3美元
今日重点评级关注：Brookline Capital：上调Intensity Therapeutics评级至"买入"，目标价3美元；Chardan Capital：维持Taysha Gene Therapies"买入"评级，目标价从9美元升至10美元
08-13 09:10
D. Boral Capital Maintains Buy on Estrella Immunopharma, Maintains $16 Price Target
D. Boral Capital analyst Jason Kolbert maintains Estrella Immunopharma (NASDAQ:ESLA) with a Buy and maintains $16 price target.
08-13 00:45
Estrella Immunopharma Announces Activation Of Second Clinical Site For Ongoing STARLIGHT-1 Phase I/II Clinical Trial Evaluating EB103 In Relapsed Or Refractory B-Cell NHL Patients
Estrella Immunopharma, Inc. (NASDAQ:ESLA) ("Estrella" or the "Company"), a clinical stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune
06-05 20:05
美股大行评级 | 英伟达、赛富时、C3.ai、Veeva Systems等获多家机构上调目标价！
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1135136987677396993.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• 摩根大通：维持Cogent Biosciences(COGT)"超配"评级，目标价从21美元升至25美元</p> <p>• Chardan Capital：维持Taysha Gene Therapies(TSHA)"买入"
05-30 09:09
Estrella Immunopharma Advances STARLIGHT-1 Clinical Trial
Estrella Immunopharma ( ($ESLA) ) just unveiled an announcement. On May 29, 202...
05-29 23:28
Estrella Immunopharma Announces First Patient Dosed In Second Cohort Of Dose Escalation Study Of Phase I/II STARLIGHT-1 Trial For EB103 To Treat Patients With Advanced B-Cell NHL
Estrella Immunopharma, Inc. (NASDAQ:ESLA) ("Estrella" or the "Company"), a clinical stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune
05-29 20:05
美股大行评级 | 潜在涨幅75%！Solar Edge获高盛升目标价至31美元，维持买入评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1099980218194210816.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Maxim Group：维持Chemomab Therapeutics(CMMB)"买入"评级，目标价从4美元升至7美元</p> <p>• Citizens Capital Markets：维持德纳维制药(DVAX)"跑赢
02-24 11:50
D. Boral Capital Maintains Buy on Estrella Immunopharma, Maintains $16 Price Target
D. Boral Capital analyst Jason Kolbert maintains Estrella Immunopharma (NASDAQ:ESLA) with a Buy and maintains $16 price target.
02-22 00:48
美股大行评级 | 潜在涨幅348%！万达生物制药获机构升目标价至20美元，维持“买入”评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1098890886600560640.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• HC Wainwright & Co.：维持Stoke Therapeutics(STOK)"买入"评级，目标价从35美元升至47美元</p> <p>• HC Wainwright & Co.：维持万达生物
02-19 10:24
Estrella Immunopharma Regains Compliance With Nasdaq Minimum Bid Price Requirement
- SEC Filing
2024-12-17 05:03
